中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
12期
11-12,15
,共3页
乳腺肿瘤%ALDH1%免疫组织化学
乳腺腫瘤%ALDH1%免疫組織化學
유선종류%ALDH1%면역조직화학
Mammary gland tumor%ALDH1%Immunohistochemistry
目的：探讨ALDH1在乳腺普通导管增生、非典型导管上皮增生以及浸润性导管癌中表达及其临床意义。方法采用免疫组织化学方法对30例正常乳腺及90例乳腺导管疾病患者的ALDH1的表达进行测定。结果 ALDH1在正常、乳腺普通导管增生、不典型导管上皮增生以及浸润性导管癌中的阳性表达率为：0%、23.3%、23.3%、60%。结论乳腺浸润性导管癌患者的ALDH1的阳性率明显高于正常乳腺及其它乳腺导管疾病，提示ALDH1的阳性表达与乳腺增生至乳腺癌变的演进，且与疾病的预后有一定的关系。
目的：探討ALDH1在乳腺普通導管增生、非典型導管上皮增生以及浸潤性導管癌中錶達及其臨床意義。方法採用免疫組織化學方法對30例正常乳腺及90例乳腺導管疾病患者的ALDH1的錶達進行測定。結果 ALDH1在正常、乳腺普通導管增生、不典型導管上皮增生以及浸潤性導管癌中的暘性錶達率為：0%、23.3%、23.3%、60%。結論乳腺浸潤性導管癌患者的ALDH1的暘性率明顯高于正常乳腺及其它乳腺導管疾病，提示ALDH1的暘性錶達與乳腺增生至乳腺癌變的縯進，且與疾病的預後有一定的關繫。
목적：탐토ALDH1재유선보통도관증생、비전형도관상피증생이급침윤성도관암중표체급기림상의의。방법채용면역조직화학방법대30례정상유선급90례유선도관질병환자적ALDH1적표체진행측정。결과 ALDH1재정상、유선보통도관증생、불전형도관상피증생이급침윤성도관암중적양성표체솔위：0%、23.3%、23.3%、60%。결론유선침윤성도관암환자적ALDH1적양성솔명현고우정상유선급기타유선도관질병，제시ALDH1적양성표체여유선증생지유선암변적연진，차여질병적예후유일정적관계。
Objective To investigate the expression of ALDH1 in usual ductal hyperplasia, atypical ductal hyperplasia and infiltra-tive ductal carcinoma and its clinical significance. Methods Immunohistochemistry method was used to detect the expression of ALDH1 in the normal mammary gland of 30 cases and mammary gland ductal disease of 90 cases of patients. Results The positive expression rate of ALDH1 in normal mammary gland, usual ductal hyperplasia, atypical ductal hyperplasia and infiltrative ductal carcinoma was 0%, 23.3%, 23.3%, 60%, respectively. Conclusion The positive rate of ALDH1 in patients with infiltrative ductal carcinoma was significantly higher than that in normal mammary gland and other mammary gland diseases, which suggests that the positive expression of ALDH1 has a certain relationship with the evolution of the mammary gland hyperplasia to mammary gland cancer and the prognosis of the disease.
